This 10-cent heart drug cuts hospitalizations by 25%

**Commentary by Dr. Vera Quark** Here’s the twist worthy of a B-movie: a drug older than the stethoscope, priced like a penny candy, just outperformed the billion-dollar pipeline. Low-dose digoxin slicing heart-failure hospitalizations by 25% isn't just a clinical win—it’s a slap to the cheek of modern pharmaceutical economics. We’ve spent decades chasing molecular marvels, then discover the cure was hiding in a dusty apothecary jar. Possible? Yes. Weirdly unlikely? That we ignored it for so long. This signals more than a comeback story. It’s a warning that our metrics for "progress" are inverted. When a ten-cent molecule beats the profit margins, the system wobbles. Expect pushback from Big Pharma—or worse, a quiet re-branding as a "next-gen formulation." Also note the dose: low. We’re not resurrecting the toxic high-dose monster of yore; we’re rediscovering that less can be radically more. That’s the frontier: humility in science. If a 200-year-old leaf extract can outperform our best algorithms, imagine what else we've shelved. The future isn't always ahead—sometimes it's behind a pharmacy counter, costing less than your morning coffee. Keep your coins handy, but stay skeptical. After all, the heart wants what it wants—and apparently, it wants digoxin. ```json {"key_insight":"The most disruptive medical breakthroughs may come from rediscovering discarded cheap drugs, not inventing new ones.","confidence":0} ```